




European College of Neuropsychopharmacology  
ECNP Research & Scholarship Foundation

# Annual Report 2019



# Contents

---

About ECNP	4
President's Introduction	6
Overview of Activities	8
- Education	9
- Science	12
- Outreach	14
Treasurer's Report	16
- Financial Statements	18
Executive Director's Report	22
Report of the External Review Board	24
Governance	26

---

This report covers two legally autonomous entities: the European College of Neuropsychopharmacology, a Swiss-constituted member society (hereafter ECNP Association); and the Netherlands-based ECNP Research and Scholarship Foundation (hereafter ECNP R&S).



Both ECNP Association and ECNP R&S are public-interest-serving entities (algemeen nut beogende instellingen – ANBI) under Dutch tax law.

For the purposes of simplicity they are here collectively referred to as “ECNP” or “the College.”

# About ECNP



ECNP is an independent European scientific association that exists to promote high-quality experimental and clinical research in applied and translational neuroscience with a view to stimulating the development of better treatments for those suffering disorders of the brain.

Our mission: to advance the science of the brain, promote better treatment and enhance brain health.

- More than 50 scientific meetings held every year
  - Spanning all aspects of scientific, educational, and regulatory dialogue
  - Bringing together researchers and clinicians from over 100 countries for fruitful scientific exchange
- 300 young scientists trained every year
  - Paid for by ECNP
- A major international journal *European Neuropsychopharmacology*

## Why we are here

By promoting new and better treatments for disorders of the brain ECNP aims to reduce the prevalence of these diseases and to alleviate the enormous suffering they cause.



Proportion of Europeans who suffer from a mental disorder annually

**38%**

(*Eur Neuropsychopharmacol* 2011) <sup>1</sup>

Number of premature deaths among people aged 25-64 due to mental health problems and suicide across Europe

**50,000**

(*OECD/EU* 2018) <sup>2</sup>



Number of deaths caused every year in Europe by brain disorders

**1.2 million**

(*OECD/EU* 2018) <sup>2</sup>



Total cost per annum of disorders of the brain to Europe

**4% of GDP**

(*OECD/EU* 2018) <sup>2</sup>



Reduction of life expectancy due to severe mental disorders

**10 to 25 years**

(*WHO* 2014) <sup>4</sup>

Number of young people aged 10-19 who die from suicide every year in Europe

**4,000**

((*WHO* 2018) <sup>3</sup>



1) H.-U. Wittchen, et al. *The size and burden of mental disorders and other disorders of the brain in Europe 2010*. *Eur Neuropsychopharmacol*. 2011 Sep;21(9):655-79. doi: 10.1016/j.euroneuro.2011.07.018.

2) *Health at a Glance: Europe 2018. State of Health in the EU Cycle*. <http://www.oecd.org/health/health-at-a-glance-europe-23056088.htm>

3) T. Paus, M. Keshavan, J. N. Giedd. *Why do many psychiatric disorders emerge during adolescence?* *Nat. Rev. Neurosci*. 2008; 9.12: 947-578

4) *Premature death among people with severe mental disorders*. [https://www.who.int/mental\\_health/management/info\\_sheet.pdf](https://www.who.int/mental_health/management/info_sheet.pdf)

# President's introduction

---

This report is being written in the shadow of the worst global public health emergency in living memory. While Covid-19 has no direct relevance for the year under review, any attempt to look back at 2019 must be through the prism of the pandemic. Given how much of the College's work relies on face-to-face interaction, there is a special poignancy to this report.

---

2019 saw ECNP at full tilt. Not only were we able to continue our full suite of activities, but were able to extend several activities and create several new ones:

- 10 more funded places to the ECNP Workshop on Clinical Research Methods
- A second ECNP Preclinical Network Educational Workshop
- The ECNP Citation Prize launched
- The ECNP Negative Results Prize in Clinical Neuroscience launched
- A new ECNP Network established, on Prevention of Mental Disorders and Mental Health Promotion
- Five Thematic Working Groups (TWGs) established
- The release of the revised second edition of the Neuroscience-based nomenclature
- The initiation of a version of the Neuroscience-based nomenclature for the patient community and general public

As we were proud to report last year: no other independent, non-governmental organisation in Europe connects more neuroscientists, psychiatrists, psychologists and neurologists, trains more early career scientists, supports more research networks, or confers more awards.

A major strategic review initiated in 2019 by my predecessor as president Celso Arango has helped us to refine our focus and goals and ensure we are optimally prepared to meet what is likely to be a challenging environment ahead. Organised around the five core values of scientific excellence, independence, innovation, and transparency, independence, the review identified three key priority areas as the cornerstones of our mission and the operative principles behind our activities:

- *Facilitating brain health solutions*, stimulating new and better research and encouraging more scientifically informed treatment and better patient outcomes.
- *Serving as a Matchmaker*, connecting the field's various stakeholders – in academia, industry, regulatory bodies and the patient community – and encouraging cross-talk and awareness-raising.
- *Providing education*, especially in the critical gap between better defined disciplines in basic neuroscience on the one side and clinical psychiatry and neurology on the other.

2019 also saw a new Executive Committee. As the first female president of ECNP, it is a particular pleasure to announce that gender balance within the Executive Committee has now become much better. Our new vice-president Elisabeth Binder (Germany), our new treasurer Catherine Harmer (United Kingdom) and our new secretary Suzanne Dickson (Sweden) are all women, with Marion Leboyer (France) and Brenda Penninx (the Netherlands) joining as councillors. Of the 62 members elected to the Executive Committee since the College's founding, a quarter have been women, but only four have held officer positions. Moreover, for the first time it was possible to self-nominate for a seat in the Executive Committee. The gender balance and better transparency seen in this Executive Committee reflects the College's determination to be leaders in the latest developments in science governance.

In addition to Marion Leboyer and Brenda Penninx, we are also very pleased to welcome David Baldwin (United Kingdom) and Andreas Reif (Germany) to the Executive Committee, and Gerry Dawson (United Kingdom), whose co-option has been renewed.

We also bid farewell to several old friends, including Laurence Lanfumey (France), Eduard Vieta (Treasurer), Stefano Pallanti (Italy), Mark J. Millan (France) and Joop van Gerven (the Netherlands). We thank them for their many years of exceptional dedication and service.

The Executive Committee, however, is only the most visible of the volunteer organs that sustains ECNP. Next to them stand our committee members and Networks members, and next to them the many speakers and presenters at our educational meetings and congresses (see pp. 27-30). Without their extraordinary commitment, energy and enthusiasm, ECNP would not exist. We are extremely fortunate to have this outstanding asset.


We cannot know the future, but we must nevertheless prepare for it. I am confident that, with the exceptional levels of high-quality volunteer engagement that ECNP enjoys, combined with our strong capital position and excellent administrative infrastructure, we are as prepared as we can be. I believe that cognitive flexibility, new ideas and approaches, will be our strongest weapon to cope with disruptive changes in the future. And this is a practice that we as scientists should be well positioned to exert.



Gitte Moos Knudsen  
President



# Overview of activities



## ECNP Association Projects and Initiatives

- European Neuropsychopharmacology
- ECNP Neuropsychopharmacology Award
- European Affairs
- ECNP Brain Day
- European Brain Council, BioMed Alliance
- ECNP Co-morbidity Study

## ECNP R&S Projects and Initiatives

- ECNP Workshop for Early Career Scientists in Europe
- ECNP Workshop on Clinical Research Methods
- ECNP School of Neuropsychopharmacology
- ECNP School of Child and Adolescent Neuropsychopharmacology
- ECNP Preclinical Network Educational Workshop
- ECNP Research Internship Programme
- ECNP Seminars
- ECNP Networks
- ECNP New Frontiers Meeting in Digital Health
- Neuroscience-based Nomenclature (Nbn)
- 'Introduction to Neuropsychopharmacology' SPOC
- ECNP Citation Prize
- ECNP Negative Results Prize

## Education

Developing the next generation of European research and clinical leaders is a longstanding ECNP priority, and a major focus of the College's resources. Stimulating translational research, promoting the best-practice use of treatments, providing methods training, assisting with career development, and encouraging early career scientists from European developing-economy countries are critical goals.

### Translational education

*Filling the gap between fundamental research and the clinic*



### ECNP Workshop for Junior Scientists in Europe

7-10 March 2019, Nice, France

Three days of intense interaction with research leaders discussing the latest advances and perspectives in translational neuroscience.

- 97 participants from 25 countries
- 11 speakers from 8 countries, including Canada
- Keynote lecture by John Cryan, University College Cork, Ireland
- 8 junior scientists funded to speak at the 32<sup>nd</sup> ECNP Congress, with 12 poster presenters receiving a € 500 Travel Award to attend the ECNP Congress

**Organisation, facilities, registration, tuition, accommodation and food provided by ECNP R&S.**

### ECNP Internship Programme

Short-term research internship opportunities for early career scientists, across the spectrum of applied and translational neuroscience.

- 15 interns per annum in institutes across Europe

**ECNP R&S provides organisational support and a € 1,000 grant to cover travel and accommodation expenses.**

*"It was a great workshop! I really enjoyed the very open and energetic atmosphere, full of enthusiastic young scientists from different fields. Please keep it that way, it's great!"*



Nearly 1,000 junior scientists pass through ECNP events every year

*"I thank you for accepting me into this amazing workshop. Across the three days I had the privilege to listen and talk to some of the top researchers in psychiatry. What an experience it has been!!"*



**ECNP Workshop on Clinical Research Methods**

6-8 November 2019, Barcelona, Spain

Three days of training on research methodology and critical approaches to the scientific literature for early career scientists.

- 131 applications, 49 participants from 27 countries
- 22 participants from 13 developing-economy countries
- 10 faculty from 3 countries

**Organisation, facilities, registration, tuition, accommodation and food provided by ECNP R&S.**

*"Everything was great, I loved the School! I really liked the idea of dividing the teams and solving certain problems. This is very inspiring! And the clinical cases themselves were very interesting!"*

**Methods training**  
*Specialist training in the theory and practice of pharmacological research*

**ECNP Preclinical Network Educational Workshop**  
26 February-1 March 2019, Athens, Greece

Hands-on training in the principles of reproducibility and robust experiment design, good research practice, reporting, data analysis and the generation of high-quality, robust, reproducible and relevant data.

- 15 competitively selected participants
- 4 international speakers
- Mixture of lectures and journal-club-style seminars

**Co-funded by ECNP R&S and Cohen Veterans Bioscience.**

  
**ECNP School of Neuropsychopharmacology**  
30 June-5 July 2019, Oxford, United Kingdom

A week-long course covering the fundamentals of neuropsychopharmacology through to the use of medications in individual indications, good clinical practice and optimal treatment and algorithms.

- 166 applications, 50 participants from 28 countries
- 18 participants from developing-economy countries
- 11 faculty from 5 countries

**Organisation, facilities, registration, tuition, accommodation and food provided by ECNP R&S.**

**Clinical training I**  
*Focused training for developing European countries*

**ECNP Seminars in Neuropsychopharmacology**  
29-31 March 2019, Palanga, Lithuania  
8-10 November 2019, Zrenjanin, Serbia  
22-24 November 2019, Budapest, Hungary

High-impact training courses for developing-economy countries, to enhance knowledge and skills in a concentrated learning environment with local and international experts.

- Palanga 34 participants
- Zrenjanin, 18 participants
- Budapest, 33 participants

**Funded by ECNP R&S.**

  
**ECNP School of Child and Adolescent Neuropsychopharmacology**  
31 March-5 April 2019, Venice, Italy

A week-long residential programme of intensive training in clinical neuropsychopharmacology for child and adolescent psychiatrists.

- 96 applications, 49 participants from 28 countries
- 21 participants from developing-economy countries
- 18 faculty from 8 countries

**Organisation, facilities, registration, tuition, accommodation and food provided by ECNP R&S.**

**Clinical training II**  
*Propagating best practices, training future clinical leaders*

**ECNP Small Private Online Course (SPOC): 'Introduction to Neuropsychopharmacology'**

Online training course to prepare clinicians in ECNP educational activities, seminars, schools and internships.

- Modules covering neuroanatomy, neurophysiology, neurogenetics, psychopharmacology, immunology and statistics

**Funded by ECNP R&S.**

*"Sharing knowledge and experience with psychiatrists from different countries, different cultural systems, different legal and regulatory schemes, different points of views... that was the best! This variety enriches the course a lot, in my opinion."*



# Science

The ability to connect Europe's applied and translational neuroscience community – from basic research all the way to clinical practice – and help to make it greater than the sum of its parts is central to ECNP's reason for existence.



## 32<sup>nd</sup> ECNP Congress

7-10 September 2019, Copenhagen, Denmark

Europe's premier showcase for new research, treatments and technologies in applied brain science. Spanning the spectrum of human mood, behaviour, cognition and emotion, the congress covers the spectrum of CNS treatment research from basic science to clinical care.

- 5,589 participants from 94 countries
- 185 invited speakers and 84 chairs
- 1,049 abstracts submitted
- 801 posters and 98 e-posters
- 482 free registrations for early career junior scientist and CDE poster presenters
- 3 Seminar Awards of € 1,000 each to selected ECNP Seminar participants
- 42 Travel Awards of € 500 each for outstanding early career scientist poster abstracts
- 9 Poster Awards of € 500 each to presenters of outstanding posters
- 40 CDE Grants of € 500 each for submitters of exceptional abstracts from developing-economy countries

**Awards and subsidies provided by the 32<sup>nd</sup> ECNP Congress Foundation.**

**Presenting the best science**  
*Disseminating the latest in CNS treatment research, building the ECNP community*



## ECNP Neuropharmacology Award

Recognises exceptional research achievements in applied and translational neuroscience, alternating between basic and clinical science.



Winner 2019:  
Inga D. Neumann  
Germany (preclinical)

**ECNP Association provides an unrestricted prize of € 10,000 – € 7,500 for the winner personally, and € 2,500 for a collaborator (or collaborators) of the winner's choice.**

## ECNP Citation Prize

Recognises and encourage impactful original research in the ECNP journal, *European Neuropsychopharmacology* (ENP). It is awarded to the most cited research paper in the preceding two years.

Recipient 2019: Christiaan J. Bachmann, Germany, et al. 'Trends in ADHD medication use in children and adolescents in five western countries, 2005-2012'. *European Neuropsychopharmacology* 27.5, May 2017, pp. 484-93.

**Supported by ECNP R&S.**

**Rewarding excellence**  
*Recognising outstanding achievement*

## Platforms for collaboration

*Stimulating collaboration across Europe*



## European Neuropsychopharmacology

International journal in applied brain science, encompassing basic and clinical and research on the effects of centrally acting agents in the broadest sense.

- 12 issues per year
- Impact factor: 4,468
- CiteScore 2019: 4.43
- Ranked 33 out of 494 in psychiatry and mental health

## World-class tools

*Providing clinicians with the benefits of the latest neuroscience insights*

## ECNP Negative Results Prize in Clinical Neuroscience

Last year ECNP launched the Best Negative Data Prize for preclinical research, the world's first prize for published 'negative' scientific results. This year, to further ECNP's goal of encouraging the publication of data where the results do not confirm the expected outcome or original hypothesis, a clinical award was initiated.

Recipient 2019: Michael Sand, United States, et al.

**Supported by ECNP R&S.**



ECNP Networks & Thematic Working Groups

## ECNP Networks and Thematic Working Groups (TWGs)

Virtual, multi-centre European research clusters for the collection and aggregation of continent-wide clinical data, and for fostering research collaboration and ideas-sharing across the translational neurosciences.

- 14 Networks, forming a matrix of disease-oriented and transnosological groups.
- 5 new TWGs launched in 2019:
  - Imuno-NeuroPsychiatry
  - iPSCs Platform for Neuropsychiatry
  - Neuromodulation
  - Pharmacogenomics and –Transcriptomics
  - Resilience
- 1 new Network on 'Digital health applied to the clinical research of brain disorders' in preparation, and to be started in 2020.
- Grants obtained by the Bipolar Disorders Network, the Prevention of Mental Disorders and Mental Health Promotion Network, and the Imuno-NeuroPsychiatry TWG, with several more major proposals in the pipeline.
- GRIDSAM multi-grid database system providing integrating data sets and facilitating more efficient data management and exploitation

**ECNP R&S funds the Networks' and TWGs expenses, including meetings, open access publications fees, and data entry, and provides grants for proposal preparation.**



## Neuroscience-based Nomenclature

International collaborative venture, led by ECNP, to develop a new nomenclature for psychotropic medications grounded in the latest advances in brain science.

- Second revised edition released – also in book form – covering 133 medications
- New Child & Adolescent version released – also in book form
- A French translation is in progress
- 40,000 downloads of the app worldwide

**Funded entirely by ECNP R&S.**

# Outreach

ECNP connects all of the key stakeholders in the CNS treatment arena, from researchers, to industry, regulators, policy-makers and patients – across the whole treatment cycle. Leveraging this position for the benefit of the field is a vital part of ECNP’s advocacy and awareness-raising role.

## European Affairs

ECNP collaborates with a number of European societies to build European capacity and advance the interests of the field.

- Biomedical Alliance in Europe – member
- European Brain Council (EBC) – founding member
- European Federation of Psychiatric Trainees (EFPT) – supporter
- Federation of European Neuroscience Societies (FENS) – founding member
- Expert Platform on Mental Health – Depression (EPD) – supporter
- Global Alliance of Mental Illness Advocacy Networks (GAMIAN-Europe) – member

Funded by ECNP Association and ECNP R&S.

## ECNP Co-morbidity Study

Major, three-year study with the London School of Economics (LSE) and Medical University of Vienna to provide a large-scale quantitative analysis of the frequency with which disorders of the brain coincide with somatic illnesses, and how this challenge is to be managed from a public health perspective.

- First study of this scale and complexity ever attempted
- Landmark for our understanding of this very important complicated area
- Due to be published in 2021

Funded by ECNP R&S.

## Moving the field forward

Bringing together key stakeholders

## Joining forces

Working together to make the case for research and treatment

## Informing the public

Communicating the latest in treatment science



## ECNP New Frontiers meeting on Neurodevelopmental disorders

10-11 March 2019, Nice, France

Unique platform for focused, high-level exchange at the intersection of research science and new treatment development. The 2019 meeting was dedicated to the role of digital medicine in therapy development for brain disorders, focusing on EU projects, regulatory, patient/family association and ethical perspectives, and innovative uses of digital medicine

- 103 applicants from 31 countries
- 83 participants from 23 countries
- 12 speakers representing from 4 countries in Europe and North America
- Follow-up session at the 32<sup>nd</sup> ECNP Congress in Copenhagen

Organisation, facilities, registration, food and speaker expenses covered by ECNP R&S.



## Regulatory Spotlight Session

10 September 2019, Copenhagen, Denmark

A special regulatory dialogue session with the European Medicines Agency (EMA), designed for open and active engagement amongst EMA stakeholders.

- Topic: Challenges and perspectives with the use of digital technology in psychiatry
- Covering regulatory, academic, and industry perspectives

Speakers and eight regulator subsidies provided by 31<sup>st</sup> ECNP Congress Foundation.



## ECNP Brain Day

57 September 2019, Copenhagen, Denmark

Public information day designed to bring the discoveries and excitement of frontier neuroscience to a general audience. Held annually in conjunction with the ECNP Congress.

- Topic: consciousness - from a (medical) brain perspective
- 4 speakers
- 500 participants

Organised in collaboration with the Lundbeck Foundation. Programme development and logistical support provided by the 32<sup>nd</sup> ECNP Congress Foundation.



# Treasurer's report

ECNP ended 2019 in a strong financial position. The greater-than-forecast result of the 31<sup>st</sup> ECNP Congress in 2018 (the proceeds of ECNP Congress fundraising are reported in the year *after* the congress takes place) combined with unexpectedly buoyant investment returns saw the College report a net underrun.

The policy of ECNP is capital containment, and the 2019 outcome is indicative of the difficulty that accurate budgeting represents when the two main sources of ECNP's income – the ECNP Congress and the investment portfolios – are both subject to significant and unpredictable year-to-year fluctuations.

The key priorities going forward continue, therefore, to be:

- Proactive tax and regulatory compliance
- Capital preservation – at agreed levels
- Budgetary discipline
- Ongoing diversification of the revenue base

Last year we offered an overview of what we saw as key risks and financial threats facing ECNP. Strikingly missing from that list was global pandemic. While Covid-19 could not have been anticipated, measures already underway to help defend the College's long-term financial position mean that ECNP is relatively well placed to meet this unprecedented challenge.

Structural costs have, as far as possible been capped. Where it has been necessary to make additional expenditures to restrict capital accumulation, these have been focused on project-specific activities, such as the co-morbidity study being undertaken with the London School of Economics and Vienna Medical School and the 'small private online course' (SPOC) now being finalised on neuropsychopharmacology. In this way we have been able to maintain our spending flexibility and responsiveness to changing market conditions.




What capital that remains above the limit agreed with the Dutch tax authorities we expect to be absorbed by the declines in the values of the portfolios as the economic effects of the corona crisis begin to be felt.

In addition to cost containment, ECNP has also been exploring ways to deploy its investments more productively, in preparation for the lower returns forecast by market analysts in the coming years, which will make it challenging to meet ECNP's income objectives. Last year the College put its asset management mandate out to bid. The result of this process was the decision to move from ING Bank to the Dutch specialty asset manager Providence Capital, in order to provide access to a wider variety of instruments, including alternative and more illiquid investments, and optimise income generation. Although the weighting of asset types has been shifted somewhat more towards equities, away from annuities, the investment policy remains conservative and focused on asset preservation. Everything we have seen in the crisis so far suggests the strategy is still the right one.

The Covid-19 disaster has already had a very significant impact on ECNP, forcing all of our meetings in 2020 to be either cancelled or transitioned to a digital format. How long the crisis lasts remains to be seen, but far-reaching consequences for how ECNP operates and funds itself are possible. We are watching events closely.

In closing, I would like to thank my predecessor Eduard Vieta, who served six years in this post and was a model treasurer.

Catherine Harmer  
*Treasurer*



# Financial statements

## ECNP Association

### Balance sheet as at 31 December 2019 (in €)

(after appropriation of profit/losses)

	31-12-2019	31-12-2018
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
<b>Accounts receivable</b>		
Debtors	-	4,740
Amounts owed by other foundations	197,522	197,522
Taxes	5,347	9,922
Other accounts receivable	190,309	182,557
	<u>393,178</u>	<u>394,741</u>
<b>Securities</b>	13,518,148	13,004,009
<b>Bank Deposits</b>	1,177,097	1,656,347
	<u>15,088,423</u>	<u>15,055,097</u>
<b>EQUITY</b>		
Other reserves	14,965,659	14,763,857
<b>CURRENT LIABILITIES</b>		
Trade creditors	53,261	227,779
Taxes	-	4,250
Other liabilities	69,503	59,211
	<u>122,764</u>	<u>291,240</u>
	<u>15,088,423</u>	<u>15,055,097</u>

### Statement of income and expenditure 2019

	Balance 2019	Balance 2018
<b>INCOME</b>		
Membership fees	89,194	81,618
Royalties	133,788	126,492
Interest and similar income	600,727	267,118
	<u>823,709</u>	<u>475,228</u>
<b>Total income</b>	823,709	475,228
<b>EXPENSES</b>		
Administration	256,898	243,941
Other expenses	147,463	162,397
European Neuropsychopharmacology	39,864	34,304
Other activities	144,454	271,393
Interest and similar charges	33,228	31,439
	<u>621,907</u>	<u>743,474</u>
<b>Total expenses</b>	621,907	743,474
<b>Net result</b>	201,802	-268,246
<b>Appropriation of result</b>		
Other reserves	201,802	-268,246

# ECNP R&S

## Balance sheet as at 31 December 2019 (in €)

(after appropriation of profit/losses)

	31-12-2019	31-12-2018
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
<b>Accounts receivable</b>		
Debtors	4,250	12,487
Amounts owed by congress foundations	270,698	279,952
Amounts owed by other foundations	-	4,250
Taxes	4,947	6,099
Other receivables	91,042	68,808
Prepayments and accrued income	41,137	39,466
	<hr/>	<hr/>
	412,074	411,062
<b>Securities</b>	9,208,186	8,870,862
<b>Bank Deposits</b>	4,185,298	4,108,011
	<hr/>	<hr/>
	13,805,558	13,389,935
<b>RESERVES, FUNDS AND LIABILITIES</b>		
<b>RESERVES AND FUNDS</b>		
Other reserves	13,665,992	13,065,315
<b>CURRENT LIABILITIES</b>		
Finance company debt	3,412	-
Trade creditors	24,014	166,804
Amounts owed to other foundations and college	11,877	12,884
Other liabilities	100,263	144,932
	<hr/>	<hr/>
	139,566	324,620
	<hr/>	<hr/>
	13,805,558	13,389,935

## Statement of income and expenditure 2019

	Balance 2019	Balance 2018
<b>INCOME</b>		
Proceeds fundraising	1,009,367	384,311
NbN books	60,340	55,360
Interest and similar income	394,479	166,883
Grants	106,321	11,134
	<hr/>	<hr/>
<b>Total income</b>	1,570,507	617,688
<b>EXPENSES</b>		
Meetings	368,673	333,952
Other activities	209,760	332,916
Other expenses	367,834	269,332
Interest and similar charges	23,563	22,724
	<hr/>	<hr/>
<b>Total expenses</b>	969,830	958,924
<b>Net result</b>	600,677	-341,236
<b>Appropriation of result</b>		
Other reserves	600,677	-285,730
Designated fund	-	-55,506
	<hr/>	<hr/>
	600,677	-341,236

# Executive Director's report

The ECNP Office is the College's secretariat, charged with the day-to-day management of its activities and the administration of its funds and resources.

The College's longstanding strategy for the ECNP Office – indeed, the rationale for the Office's existence – has been, as the College grows and evolves in scope and sophistication, to insource functions, that can be done more cheaply and effectively inhouse.

In the case of the ECNP Congress, over the last 14 years the ECNP Office has taken over, step by step, the entirety of its logistical operations. This process is the basis of the ECNP Congress's reputation for being exceptionally well organised, a reputation of which we are very proud.

In 2019 industry and exhibition activities for the congress were brought inhouse and the decision was taken that the last congress tasks contracted to a professional congress organiser (PCO) – registration, financial administration and onsite management – would also be performed inhouse from the 2020 congress onwards. The transition of the 2020 ECNP Congress to a virtual platform, and the greater manoeuvrability and responsiveness it has given us, even further vindicates this decision.

With the costs saved from insourcing and fewer working hours due to parental leave, the ECNP Office has been able to expand the team with an assistant manager registration, Jevgenija Kiknavelidze, joining in 2019 and, at the start of 2020, an assistant project manager Congresses & Meetings, Clarine Sies, as well as a bookkeeper, Philip van Daal. We are very happy to welcome Jevgenija, Clarine and Philip to the team.

Because of the additional investment in the ECNP Congress, as from 2020 the total expenses of the ECNP Office, including staff and other housing costs, will be charged 15% to ECNP Association (formerly 20%), 20% to the ECNP Research and Scholarship Foundation, and 65% to the Congress foundations (formerly 60%).

An additional major source of activity for the ECNP Office were the EU projects, for which the ECNP Office provides a variety of dissemination support services. In 2019 there were no less than nine of these:

- AIMS-2-TRIALS – Autism Innovative Medicine Studies-2-Trials (IMI2)
- c4c – conect4children (IMI2)
- EBRA – European Brain Research Area (H2020)
- EQIPD – European Quality in Preclinical Data (IMI2)
- Eat2beNICE – Effects of Nutrition and Lifestyle on Impulsive, Compulsive, and Externalizing behaviours (H2020)
- HEROES – The locus coeruleus: at the crossroad of dementia syndromes (JPND)
- PRIME – PRInting platform for the next generation of active Microfluidic dEVICES (H2020)
- PRISM – Psychiatric Ratings using Intermediate Stratified Markers (IMI2)

Supporting these projects, which we see as an important service to ECNP's research community, will continue to be a priority in 2020.

Planning for the future has always meant modelling various scenarios. The corona crisis has rendered that planning enormously more complicated. Already ECNP activities have been transformed; the only question now is how many of these transformations will not be transitory. The potential for disruptive change in the College's business model is real. In these trying times, I am very pleased to have such a strong and effective ECNP Office team.

Alexander Schubert  
*Executive Director*



# Report of the ECNP Review Board

The role of the ECNP Review Board (ERB) provides independent advice to the Executive Committee on the quality and appropriateness of ECNP's scientific activities and rigour of its governance structure. The ERB meets twice per year: on the occasion of the the annual ECNP Workshop in Nice in March; and at the beginning of the ECNP Congress in September or October. Each of these meetings is accompanied by meetings between the ERB and the ECNP president and Executive Committee members.

The current members of the ERB are Hans-Jürgen Möller (Germany), chair, Carlo Altamura (Italy), Kim Do (Switzerland), and Naomi Fineberg (United Kingdom). This year is the last of Carlo Altamura's term, and we thank him for his outstanding contributions as an ERB member. He will be replaced in 2020 by Astrid Linthorst (United Kingdom).

In 2019 the ERB reviewed the investment policy, the pre-clinical/clinical balance, the early career scientist programmes, and the member engagement activities. Furthermore, the ERB finalised its rotation policy and identified a fourth ERB member to replace Carlo Altamura.

The ERB came to the following conclusions and recommendations:

- ECNP's investment strategy is responsible and its asset management soundly organised. Due to this and a conservative and careful spending policy, the financial situation of ECNP is very solid.
- Innovations in the ECNP Congress are interesting and welcome. Besides innovations in the scientific and educational programme, additional activities, such as health- and diet-related activities or discussions about work-life balance and gender issues, are very attractive.
- A clear distinction in the printed programme between SPC-regulated events and satellite symposia or other events sponsored by the pharmaceutical companies is advisable.

- Early career scientist programmes continue to be excellent and should continue to be a key focus.
- Besides the current education programmes, targeted programmes for mid-career clinicians would also be helpful. The proposed educational day, to be attached to the congress, will give an opportunity for this.
- The core discipline of neuropsychopharmacology still needs a voice – especially in these times, when we are faced with so many disappointments and criticism in this field. Thus the decision of the EC to continue with the name ECNP is seen as very meaningful.
- Other new or planned activities, such as the New Frontiers Meeting, with European and US regulators, are especially welcome.

ECNP is under all aspects in a very good shape. The richness of all kinds of scientific and educational activities is very impressive. Besides the excellent work of the Executive Committee, the outstanding work of the ECNP Office in Utrecht, with highly competent and motivated staff, has to be mentioned in this content. Among the many other positive developments, the ERB would like to highlight in conclusion the fact that the ECNP Office is now taking over the whole organisation of the congress, which saves not only money, but also will lead to better service to members and participants.

Hans-Jürgen Möller  
*Chair*




# Governance

ECNP operates as an amalgamation of different entities. These entities are legally autonomous and self-sustaining, but each represents the ECNP brand and serves coordinated goals.

These entities are:

- The European College of Neuropsychopharmacology (“ECNP Association”), a Swiss-constituted member society permanently based in the Netherlands
- The ECNP Research and Scholarship Foundation (“ECNP R&S”), a Dutch-constituted foundation legally domiciled in the Netherlands
- The ECNP Congress Foundations, one per congress; Dutch-constituted foundations legally domiciled in the Netherlands
- The Stichting Buro ECNP, a Dutch-constituted foundation legally domiciled in the Netherlands



ECNP Association, ECNP R&S and the ECNP Congress Foundations are all public-interest-serving entities (algemeen nut beogende instellingen – ‘ANBI’) under Dutch tax law.

The Stichting Buro ECNP is the legal umbrella housing the ECNP Office.

## Membership

- 594 Ordinary members
- 113 Associate members
- 128 Corresponding members
- 24 Emeritus members

**859 total members**

**Top ten countries:**

1. United Kingdom
2. Germany
3. The Netherlands
4. Spain
5. Italy
6. Sweden
7. United States
8. Russia
9. France
10. Switzerland

## Re-imbusement

**ECNP Association**

The presidency comes with a grant of € 15,000 and each officer position (vice president, president-elect, past president, secretary, treasurer) € 4,000 to assist with secretarial expenses, payable to the institution of primary employment. Each member of the Executive Committee receives a lump sum of € 1,500 to cover incidental expenses related to their role.

**ECNP R&S**

Members of the board do not receive remuneration for their role.

**ECNP Congress Foundations**

The chair of the Scientific Programme Committee receives € 6,000 for secretarial assistance, payable to his/her institution of primary employment. Other members of the Scientific Programme Committee receive € 1,000 for the duration of their term to cover associated expenses.

**Stichting Buro ECNP**

Members of the board do not receive remuneration for their role.

## ECNP Association

**Executive Committee 2019-2022**

**Officers**

Gitte Moos Knudsen, Denmark, President  
 Martien Kas, The Netherlands, President-elect  
 Elisabeth Binder, Germany, Vice-president  
 Celso Arango, Spain, Past-president  
 Suzanne Dickson, Sweden, Secretary  
 Catherine Harmer, United Kingdom, Treasurer

**Councillors**

David Baldwin, United Kingdom, Councillor  
 Damiaan Denys, The Netherlands, Councillor  
 Marion Leboyer, France, Councillor  
 Brenda Penninx, The Netherlands, Councillor  
 Andreas Reif, Germany, Councillor, also Chair SPC  
 32<sup>nd</sup>, 33<sup>rd</sup>, 34<sup>th</sup> ECNP Congress  
 Gil Zalsman, Israel, Councillor

**Non-voting Members**

Gerry Dawson, United Kingdom, Co-opt Member  
 Andreas Meyer-Lindenberg, Germany, Editor-in-Chief  
*European Neuropsychopharmacology*  
 Alexander Schubert, The Netherlands, Executive Director

**Award Committee**

Andreas Meyer-Lindenberg, Germany, Chair  
 Monica DiLuca, Italy  
 René Kahn, United States  
 Wim van den Brink, The Netherlands

**ECNP Review Board**

Hans-Jürgen Möller, Germany, Chair  
 Kim O. Do, Switzerland  
 Naomi Fineberg, United Kingdom  
 Astrid Linthorst, United Kingdom

### **Nominating Committee (for the 2019-2021 Executive Committee)**

Guy Goodwin, United Kingdom, Past President, Chair  
Celso Arango, Spain, President  
Wim van den Brink, The Netherlands  
Tomas Hökfelt, Sweden  
Gitte Knudsen, Denmark, President-Elect  
Ruth McKernan, United Kingdom  
Hans-Jürgen Möller, Germany

### **European Neuropsychopharmacology Editorial Board**

Andreas Meyer-Lindenberg, Germany, Editor-in-Chief  
Michael Davidson, Israel  
Jaanus Harro, Estonia  
Rafael Maldonado, Spain  
Brian Morris, United Kingdom  
Andreas Reif, Germany  
Thomas. G. Schulze, Germany  
Eduard Vieta, Spain

## **ECNP R&S**

### **Board 2019-2022**

Gitte Moos Knudsen, Denmark,  
Suzanne Dickson, Sweden, Secretary  
Catherine Harmer, United Kingdom, Treasurer

### **Early Career Advisory Panel (ECAP)**

Nils Opel, Germany, Chair  
Celso Arango, Spain, *representative Executive  
Committee*  
Sofi Atshemyan, Republic of Armenia  
Christine Fülling, Ireland  
Judith Harrison, United Kingdom  
Aiste Lengvenyte, Lithuania

### **ECNP Networks Board**

Gitte Moos Knudsen, Denmark, Chair  
Nic van der Wee, The Netherlands,  
Scientific Co-ordinator

### **ECNP Networks Taskforce**

*ADHD*: Barbara Franke, The Netherlands;  
Andreas Reif, Germany  
*Anxiety Disorders (ADRN)*: Borwin Bandelow,  
United Kingdom; Katharina Domschke, Germany  
*Bipolar Disorders (ENBREC)*: Michael Bauer, Germany;  
Lars Kessing, Germany; Ole Andreassen, Norway  
*Child and Adolescent Neuropsychopharmacology*:  
Alessandro Zuddas, Italy; Carmen Moreno, Spain  
*Down Syndrome and Other Genetic Development  
Disorders (DSG2D)*: Marie-Claude Potier, France;  
Mara Dierssen, Spain  
*Experimental Medicine*: Gerry Dawson, United Kingdom  
*Neuroimaging*: Hilleke Hulshoff Pol, The Netherlands;  
Nikolaos Koutsouleris, Germany  
*Nutrition*: Suzanne Dickson, Sweden; Roger Adan,  
The Netherlands  
*Obsessive Compulsive and Related Disorders (OCRN)*:  
José Manuel Menchón, Spain  
*Preclinical Data Forum*: Anton Bespalov, Germany;  
Thomas Steckler, Belgium  
*Schizophrenia*: Silvana Galderisi, Italy; István Bitter,  
Hungary  
*Suicide*: Danuta Wasserman, Sweden; Vladimir Carli,  
Sweden  
*Traumatic Stress*: Eric Vermetten, The Netherlands;  
Joseph Zohar, Israel  
*Prevention of Mental Disorders and Mental Health  
Promotion*: Paolo Fusar-Poli, United Kingdom/Italy

### **Educational Committee**

David Baldwin, United Kingdom, *Chair*  
Francisca Cirulli, Italy  
Christina Dalla, Greece  
Katharina Domschke, Germany  
Milan Latas, Serbia  
Eduard Maron, Estonia  
Marie-Claude Potier, France  
David Slattery, Germany

E-Learning and ECNP Seminars: Gil Zalsman, Israel

### **New Frontiers Meeting Committee**

Celso Arango, Spain, *Chair*  
Gerry Dawson, United Kingdom  
Hilkka Kärkkäinen, GAMIAN-Europe  
Martien Kas, The Netherlands  
Hugh Marston, United Kingdom  
Luca Pani, United States  
Stephane Pollentier, Germany  
Thomas Steckler, Belgium

### **Neuroscience-based Nomenclature Task Force**

Joseph Zohar, Israel, *Chair*  
Pierre Blier, Canada  
Filippo Drago, Italy  
Guy Goodwin, United Kingdom  
David Kupfer, United States  
Hans-Jürgen Möller, Germany  
David Nutt, United Kingdom  
Stephen Stahl, United States  
Hiroyuki Uchida, Japan  
Shigeto Yamawaki, Japan

### **Workshop Committee**

Suzanne Dickson, Sweden, *Chair*  
Roger Adan, The Netherlands  
Elisabeth Binder, Germany  
Damiaan Denys, The Netherlands  
Barbara Franke, The Netherlands  
Catherine Harmer, United Kingdom  
Judith Harrison, United Kingdom  
Jaanus Harro, Estonia  
Martien Kas, The Netherlands  
Marion Leboyer, France  
Juan Carlos Leza, Spain  
Andreas Reif, Germany  
Michele Roche, Ireland

## **32<sup>nd</sup> ECNP Congress Foundation**

### **Board**

Gitte Moos Knudsen, Chair and Treasurer  
Alexander Schubert, The Netherlands, Secretary  
Andreas Reif, Germany

### **Scientific Programme Committee**

Andreas Reif, Germany, Chair  
David Baldwin, United Kingdom, Chair Educational  
Committee  
Andreas Meyer-Lindenberg, Germany, Editor-in-Chief  
*European Neuropsychopharmacology*  
Claudia Bagni, Italy  
Mar Carreño, Spain  
Jan Deussing, Germany  
Barbara Franke, The Netherlands  
Judith Homberg, The Netherlands  
Lars Kessing, Denmark  
Ulrike Lueken, Germany  
Ingrid Melle, Norway

Marcus Munafo, United Kingdom  
Maurizio Popoli, Italy  
Diane Purper-Ouakil, France  
Anja Schneider, Germany  
Gregers Wegener, Denmark

### **Scientific Advisory Panel for 2017-2020**

Roger Adan, The Netherlands  
Laura Airas, Finland  
Pino Alonso, Spain  
Frank Bellivier, France  
Anton Y. Bespalov, Germany  
István Bitter, Hungary  
Michael Bloomfield, United Kingdom  
Jan Booij, The Netherlands  
Wim van den Brink, The Netherlands  
Jan K. Buitelaar, The Netherlands  
Jocelyne Caboche, France  
Josefina Castro-Fornieles, Spain  
Annamaria Cattaneo, United Kingdom  
Ginetta Collo, Italy  
Andrea Danese, United Kingdom  
Andrea de Bartolomeis, Italy  
Suzanne L. Dickson, Sweden  
Katharina Domschke, Germany  
Filippo Drago, Italy  
Anne Eckert, Switzerland  
Angelika Erhardt, Germany  
Mia Ericson, Sweden  
Karen Ersche, United Kingdom  
David P. Finn, Ireland  
Gabriele Fischer, Austria  
Kevin C.F. Fone, United Kingdom  
Barbara Franke, The Netherlands  
Christine Freitag, Germany  
Vibe G. Frokjaer, Denmark  
Silvana Galderisi, Italy  
Alexander Gerhard, United Kingdom  
Mark A. Geyer, United States  
Philip Gorwood, France  
Iria Grande, Spain  
Edna Grünblatt, Switzerland  
Antoni Gual, Spain  
Gregor Hasler, Switzerland  
Martin Hatzinger, Switzerland  
Judith Homberg, The Netherlands  
Iiris Hovatta, Finland  
Michal Hrdlicka, Czech Republic  
Evgeny Krupitsky, Russia  
Marion Leboyer, France  
Klaus-Peter Lesch, Germany  
Stefan Leucht, Germany

Paul John Lucassen, The Netherlands  
 Anabel Martinez-Aran, Spain  
 David Mataix-Cols, Sweden  
 Raymond Mongeau, France  
 Carmen Moreno, Spain  
 Arne Mørk, Denmark  
 Rainald Mössner, Germany  
 Dieter Naber, Germany  
 Inga Neumann, Germany  
 Florence Noble, France  
 Mariusz Papp, Poland  
 Mara Parellada, Spain  
 Walter Pirker, Austria  
 Edith Pomarol-Clotet, Spain  
 Marie-Claude Potier, France  
 Christopher Pryce, Switzerland  
 Andreas Reif, Germany  
 Emma Robinson, United Kingdom  
 Michelle Roche, Ireland  
 Henricus G. Ruhe, The Netherlands  
 Rainer Rupprecht, Germany  
 Janusz K. Rybakowski, Poland  
 Koen Schruers, The Netherlands  
 David A. Slattery, Germany  
 Iris E. C. Sommer, The Netherlands  
 Daniel Souery, Belgium  
 Florence Thibaut, France  
 Marta Torrens, Spain  
 Elizabeth Tunbridge, United Kingdom  
 Louk J. Vanderschuren, The Netherlands  
 Elisabet Vilella, Spain  
 Odile Viltart, France  
 Ina Weiner, Israel  
 Abraham Weizman, Israel  
 Sue Wilson, United Kingdom  
 Guido van Wingen, The Netherlands  
 Aysegül Yildiz, Turkey  
 Alessandro Zuddas, Italy

## Stichting Buro ECNP

### Board

Gitte Moos Knudsen, Chair  
 Suzanne Dickson, Secretary and Treasurer

### ECNP Office

Alexander Schubert, Executive Director  
 Iris Allebrandi, Director Congresses & Meetings  
 Ellen van den Berg, Director Operations  
 Ligia Bohn, Senior Project Manager Communication  
 Godelieve Escartín, Senior Project Manager  
 Congresses & Meetings  
 Eline Dimmendaal, Project Manager Congresses &  
 Meetings  
 Annemieke Heuvink, Project Manager Congresses &  
 Meetings  
 Melinda Spitzer, Project Manager Congresses &  
 Meetings  
 Corine ten Brink, Project Manager Science & Education  
 Wendy Schouten, Project Manager Science &  
 Education  
 Petra Hoogendoorn, Project Manager Science,  
 Education & Communication  
 Matteo Bason, Scientific Officer  
 Maxime Besutti, Assistant Project Manager  
 Communication  
 Rilana Rahaël, Financial Administrative Assistant  
 Jevgenija Kiknavelidze, Assistant Manager  
 Registration

### Key Identification Numbers

#### ECNP Association

VAT number: NL823523974B01  
 RSIN: 823523974

#### ECNP R&S

VAT number: NL807967087B01  
 RSIN: 807967087  
 Chamber of commerce number: 41215196



*ECNP is the largest  
 non-institutional  
 supporter of  
 education and  
 research in applied  
 neuroscience  
 in Europe*





**ECNP Office**

T: +31 88 75 69 555

E: [secretariat@ecnp.eu](mailto:secretariat@ecnp.eu)

[www.ecnp.eu](http://www.ecnp.eu)

**Postal Address**

PO Box 85410

3508 AK Utrecht

The Netherlands

**Visiting Address**

Bolognalaan 28

3584 CJ Utrecht

The Netherland

